How much is the latest price of regorafenib in 2024?

Regorafenib (Regorafenib) is an oral multi-target inhibitor that is widely used in the treatment of advanced malignant tumors, especially malignant tumors such as advanced colorectal cancer and gastrointestinal stromal tumor (GIST). It belongs to the category of targeted therapy drugs and is considered one of the important milestones in the field of tumor treatment because of its unique mechanism of action.

Regorafenib has been launched in China and is included in medical insurance. Patients can buy it domestically at a price of about four to five thousand yuan. Please consult the local hospital pharmacy for specific prices and medical insurance reimbursement. There are original drugs and generic drugs abroad. The original drugs are mainly Turkish original drugs, and the price is more than 1,000 yuan. Generic drugs are available in Laos, India and Bangladesh, with prices ranging from a few hundred yuan to more than a thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.

Regorafenib inhibits tumor growth and spread by interfering with multiple signaling pathways simultaneously. Its main functions include inhibiting vascular endothelial growth factor receptor (VEGFR), mitogen-activated protein kinase (RAF), and tumor microenvironment-related receptor tyrosine kinase (PDGFR), matrix metalloproteinase (KIT), RET and other targets. This enables Regorafenib to inhibit tumor angiogenesis, reduce tumor cell proliferation and invasion, and promote tumor cell apoptosis, thereby inhibiting tumor growth.

In clinical studies,regorafenib (regorafenib) has proven to have significant efficacy in the treatment of tumors such as advanced colorectal cancer andGIST. Regorafenib (regorafenib) is often used as a first- or later-line treatment option for patients whose disease has progressed despite previous treatment. In addition, Regorafenib is also used to treat a variety of malignant tumors such as metastatic liver cancer and metastatic thyroid cancer.

Compared with traditional chemotherapy drugs, Regorafenib is more targeted and therefore generally brings fewer toxic side effects and better tolerability. However, Regorafenib may also cause some adverse reactions, including but not limited to hypertension, hand-foot syndrome, fatigue, etc. Therefore, when using regorafenib , doctors need to closely monitor the patient's condition and adjust the dose or suspend treatment as needed.